Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
Sign Up to like & getrecommendations! Published in 2022 at "PLoS Medicine"
DOI: 10.1101/2022.02.24.22271445
Abstract: Background Heterologous boost vaccination has been proposed as an option to elicit stronger and broader, or longer-lasting immunity. We assessed the safety and immunogenicity of heterologous immunization with a recombinant adenovirus type-5-vectored COVID-19 vaccine (Convidecia)… read more here.
Keywords: day; convidecia; zf2001; boost ... See more keywords